The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Fatty Liver Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Fatty liver drugs refer to medications or pharmaceutical treatments used in the management and treatment of fatty liver disease. Fatty liver disease, also known as hepatic steatosis, is a condition characterized by the accumulation of excess fat in the liver cells.
The global Fatty Liver Drugs market size is expected to reach US$ 29870 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Fatty Liver Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Fatty Liver Drugs market. ALD, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the NAFLD segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Fatty Liver Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Fatty Liver Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Fatty Liver Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Fatty Liver Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Fatty Liver Drugs covered in this report include Pfizer, Gilead Sciences, Astra Zenca, Immuron, Novartis, Takeda, Allergan, Intercept Pharmaceuticals and Conatus, etc.
The global Fatty Liver Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Gilead Sciences
Astra Zenca
Immuron
Novartis
Takeda
Allergan
Intercept Pharmaceuticals
Conatus
Merk
Madrigal
Hepion Pharmaceuticals
Global Fatty Liver Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Fatty Liver Drugs market, Segment by Type:
ALD
NAFLD
Global Fatty Liver Drugs market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Fatty Liver Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Fatty liver drugs refer to medications or pharmaceutical treatments used in the management and treatment of fatty liver disease. Fatty liver disease, also known as hepatic steatosis, is a condition characterized by the accumulation of excess fat in the liver cells.
The global Fatty Liver Drugs market size is expected to reach US$ 29870 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Fatty Liver Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Fatty Liver Drugs market. ALD, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the NAFLD segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Fatty Liver Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Fatty Liver Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Fatty Liver Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Fatty Liver Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Fatty Liver Drugs covered in this report include Pfizer, Gilead Sciences, Astra Zenca, Immuron, Novartis, Takeda, Allergan, Intercept Pharmaceuticals and Conatus, etc.
The global Fatty Liver Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Gilead Sciences
Astra Zenca
Immuron
Novartis
Takeda
Allergan
Intercept Pharmaceuticals
Conatus
Merk
Madrigal
Hepion Pharmaceuticals
Global Fatty Liver Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Fatty Liver Drugs market, Segment by Type:
ALD
NAFLD
Global Fatty Liver Drugs market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Fatty Liver Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Fatty Liver Drugs
1.1 Fatty Liver Drugs Market Overview
1.1.1 Fatty Liver Drugs Product Scope
1.1.2 Fatty Liver Drugs Market Status and Outlook
1.2 Global Fatty Liver Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Fatty Liver Drugs Market Size by Region (2018-2029)
1.4 Global Fatty Liver Drugs Historic Market Size by Region (2018-2023)
1.5 Global Fatty Liver Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Fatty Liver Drugs Market Size (2018-2029)
1.6.1 North America Fatty Liver Drugs Market Size (2018-2029)
1.6.2 Europe Fatty Liver Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Fatty Liver Drugs Market Size (2018-2029)
1.6.4 Latin America Fatty Liver Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Fatty Liver Drugs Market Size (2018-2029)
2 Fatty Liver Drugs Market by Type
2.1 Introduction
2.1.1 ALD
2.1.2 NAFLD
2.2 Global Fatty Liver Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Fatty Liver Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Fatty Liver Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Fatty Liver Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Fatty Liver Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Fatty Liver Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Fatty Liver Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Fatty Liver Drugs Revenue Breakdown by Type (2018-2029)
3 Fatty Liver Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Fatty Liver Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Fatty Liver Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Fatty Liver Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Fatty Liver Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Fatty Liver Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Fatty Liver Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Fatty Liver Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Fatty Liver Drugs Revenue Breakdown by Application (2018-2029)
4 Fatty Liver Drugs Competition Analysis by Players
4.1 Global Fatty Liver Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Fatty Liver Drugs as of 2022)
4.3 Date of Key Players Enter into Fatty Liver Drugs Market
4.4 Global Top Players Fatty Liver Drugs Headquarters and Area Served
4.5 Key Players Fatty Liver Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Fatty Liver Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Fatty Liver Drugs Products, Services and Solutions
5.1.4 Pfizer Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Gilead Sciences
5.2.1 Gilead Sciences Profile
5.2.2 Gilead Sciences Main Business
5.2.3 Gilead Sciences Fatty Liver Drugs Products, Services and Solutions
5.2.4 Gilead Sciences Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Gilead Sciences Recent Developments
5.3 Astra Zenca
5.3.1 Astra Zenca Profile
5.3.2 Astra Zenca Main Business
5.3.3 Astra Zenca Fatty Liver Drugs Products, Services and Solutions
5.3.4 Astra Zenca Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Immuron Recent Developments
5.4 Immuron
5.4.1 Immuron Profile
5.4.2 Immuron Main Business
5.4.3 Immuron Fatty Liver Drugs Products, Services and Solutions
5.4.4 Immuron Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Immuron Recent Developments
5.5 Novartis
5.5.1 Novartis Profile
5.5.2 Novartis Main Business
5.5.3 Novartis Fatty Liver Drugs Products, Services and Solutions
5.5.4 Novartis Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis Recent Developments
5.6 Takeda
5.6.1 Takeda Profile
5.6.2 Takeda Main Business
5.6.3 Takeda Fatty Liver Drugs Products, Services and Solutions
5.6.4 Takeda Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Takeda Recent Developments
5.7 Allergan
5.7.1 Allergan Profile
5.7.2 Allergan Main Business
5.7.3 Allergan Fatty Liver Drugs Products, Services and Solutions
5.7.4 Allergan Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Allergan Recent Developments
5.8 Intercept Pharmaceuticals
5.8.1 Intercept Pharmaceuticals Profile
5.8.2 Intercept Pharmaceuticals Main Business
5.8.3 Intercept Pharmaceuticals Fatty Liver Drugs Products, Services and Solutions
5.8.4 Intercept Pharmaceuticals Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Intercept Pharmaceuticals Recent Developments
5.9 Conatus
5.9.1 Conatus Profile
5.9.2 Conatus Main Business
5.9.3 Conatus Fatty Liver Drugs Products, Services and Solutions
5.9.4 Conatus Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Conatus Recent Developments
5.10 Merk
5.10.1 Merk Profile
5.10.2 Merk Main Business
5.10.3 Merk Fatty Liver Drugs Products, Services and Solutions
5.10.4 Merk Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Merk Recent Developments
5.11 Madrigal
5.11.1 Madrigal Profile
5.11.2 Madrigal Main Business
5.11.3 Madrigal Fatty Liver Drugs Products, Services and Solutions
5.11.4 Madrigal Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Madrigal Recent Developments
5.12 Hepion Pharmaceuticals
5.12.1 Hepion Pharmaceuticals Profile
5.12.2 Hepion Pharmaceuticals Main Business
5.12.3 Hepion Pharmaceuticals Fatty Liver Drugs Products, Services and Solutions
5.12.4 Hepion Pharmaceuticals Fatty Liver Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Hepion Pharmaceuticals Recent Developments
6 North America
6.1 North America Fatty Liver Drugs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Fatty Liver Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Fatty Liver Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Fatty Liver Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Fatty Liver Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Fatty Liver Drugs Market Dynamics
11.1 Fatty Liver Drugs Industry Trends
11.2 Fatty Liver Drugs Market Drivers
11.3 Fatty Liver Drugs Market Challenges
11.4 Fatty Liver Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
